Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NET transcriptome monitoring during 177Lu-octreotate PRRT
NL-OMON41217Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET) and Carcinoid Tumor (CT), sponsored by Erasmus MC. Primary endpoints: Change in circulating NEN transcripts during and after PRRT, Correlation between transcript changes and final tumor response and 1 more. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NL-OMON41217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41217.